SCHEMBL19682913

SCHEMBL19682913

CC(C)(C)OC(=O)n1ccc2c(S(=O)(=O)Cl)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
NOTUM Q6P988 1/20 0.41
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
ACLY P53396 1/20 0.38
AKT1 P31749 1/20 0.38
PIM1 P11309 1/20 0.38
MARK3 P27448 1/20 0.38
MAP4K2 Q12851 1/20 0.38
CAMK2B Q13554 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
BUB1 O43683 1/20 0.37
BCHE P06276 1/20 0.37
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
ACHE P22303 1/20 0.36
HTR6 P50406 2/20 0.36
STS P08842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20789959 0.86 L3MBTL1 (0.42) L3MBTL1NOTUMBRD4CREBBPACLY
SCHEMBL30763696 0.82 NOTUM (0.63) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL2878376 0.82 NOTUM (0.63) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL424580 0.80 L3MBTL1 (0.48) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL3836430 0.80 L3MBTL1 (0.45) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL18487086 0.80 L3MBTL1 (0.45) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL22831319 0.80 NOTUM (0.44) L3MBTL1NOTUMHTR6FABP4
SCHEMBL1314389 0.79 NOTUM (0.43) L3MBTL1NOTUMBRD4CREBBPACLY
SCHEMBL18788881 0.79 L3MBTL1 (0.44) L3MBTL1NOTUMBRD4CREBBPAKT1
SCHEMBL1284244 0.79 L3MBTL1 (0.44) L3MBTL1NOTUMBRD4CREBBPAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466934-B1 SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER TAIHO PHARMACEUTICAL CO LTD (JP) 2024-03-27 EP disclosed
US-11634395-B2 Sulfonamide compound or salt thereof Taiho Pharmaceutial Co., Ltd. (JP) 2023-04-25 US disclosed
CN-109563057-B Sulfonamide compound or salt thereof 大鹏药品工业株式会社 2022-06-24 CN disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 L3MBTL1 2379/4885NOTUM 2538/4885BRD4 1290/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 L3MBTL1 2379/4885NOTUM 2538/4885BRD4 1290/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 L3MBTL1 2379/4885NOTUM 2538/4885BRD4 1290/4885
US-11634395-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 L3MBTL1 2379/4885NOTUM 2538/4885BRD4 1290/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B L3MBTL1 1769/4885NOTUM 4221/4885BRD4 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.